Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis

The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a simplified treatment option for antiretroviral therapy (ART)-naïve patients with baseline HIV-1 RNA (BLVL) of ≤100,000 copies/mL. The aim of this analysis...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Behrens, Georg, Rijnders, Bart, Nelson, Mark, Orkin, Chloe, Cohen, Calvin, Mills, Anthony, Elion, Richard A., Vanveggel, Simon, Stevens, Marita, Rimsky, Laurence, Thorpe, David, Bosse, Matthew, White, Kirsten, Zhong, Lijie, DeMorin, Jennifer, Chuck, Susan K.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Mary Ann Liebert, Inc. 2014
Konular:
Clinical and Epidemiologic Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3985528/
https://ncbi.nlm.nih.gov/pubmed/24660840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/apc.2013.0310
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller